Brokerages be expecting VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to announce $310,000.00 in gross sales for the current fiscal quarter, Zacks Financial commitment Exploration studies. Two analysts have issued estimates for VistaGen Therapeutics’ earnings, with the maximum sales estimate coming in at $310,000.00 and the least expensive estimate coming in at $300,000.00. The firm is envisioned to announce its up coming earnings report on Monday, July 5th.
According to Zacks, analysts assume that VistaGen Therapeutics will report whole calendar year product sales of $930,000.00 for the existing monetary 12 months, with estimates ranging from $900,000.00 to $960,000.00. For the upcoming yr, analysts hope that the business will article income of $1.23 million, with estimates ranging from $1.20 million to $1.25 million. Zacks Expenditure Research’s gross sales calculations are a signify average primarily based on a survey of offer-side analysts that deal with VistaGen Therapeutics.
VistaGen Therapeutics (NASDAQ:VTGN) final launched its quarterly earnings data on Thursday, February 11th. The organization described ($.07) earnings for every share for the quarter, lacking the Thomson Reuters’ consensus estimate of ($.05) by ($.02). The organization experienced profits of $.31 million for the quarter, in comparison to analysts’ anticipations of $.33 million.
A variety of brokerages have recently commented on VTGN. William Blair raised VistaGen Therapeutics from a “market place complete” score to an “outperform” score in a report on Monday, January 4th. Zacks Financial investment Investigation decreased shares of VistaGen Therapeutics from a “hold” score to a “sell” score in a study report on Thursday, February 18th. Maxim Team boosted their price objective on shares of VistaGen Therapeutics from $3.00 to $5.00 in a investigate observe on Tuesday, December 22nd. Finally, Jefferies Monetary Group initiated protection on shares of VistaGen Therapeutics in a study observe on Thursday, February 25th. They issued a “buy” ranking and a $6.00 goal cost on the inventory. A person analyst has rated the stock with a offer ranking and four have presented a purchase ranking to the organization. VistaGen Therapeutics presently has a consensus score of “Purchase” and an ordinary target selling price of $4.44.
NASDAQ VTGN opened at $2.35 on Monday. VistaGen Therapeutics has a fifty-two week lower of $.30 and a fifty-two 7 days higher of $3.18. The stock’s 50-working day relocating common is $2.23 and its two-hundred day going normal is $1.30. The company has a market place cap of $332.98 million, a P/E ratio of -4.90 and a beta of .52.
Institutional buyers and hedge funds have not too long ago acquired and sold shares of the company. Orbimed Advisors LLC acquired a new placement in VistaGen Therapeutics for the duration of the 4th quarter valued at $14,550,000. Acuta Funds Partners LLC obtained a new posture in shares of VistaGen Therapeutics in the fourth quarter valued at $14,550,000. Ikarian Capital LLC acquired a new placement in VistaGen Therapeutics in the fourth quarter worthy of $8,703,000. Ghost Tree Funds LLC acquired a new stake in VistaGen Therapeutics in the 4th quarter valued at $4,734,000. At last, Asymmetry Capital Management L.P. obtained a new placement in shares of VistaGen Therapeutics in the 4th quarter valued at $4,345,000. 3.13% of the inventory is owned by institutional buyers.
About VistaGen Therapeutics
VistaGen Therapeutics, Inc, a clinical-phase biopharmaceutical company, engages in producing and commercializing many medications with the potential to care for anxiety, despair, and other issues of the central anxious process (CNS). The firm’s CNS pipeline involves PH94B, a fast-onset neuroactive nasal spray, which is in preparing for Phase III enhancement for the acute procedure of anxiousness in grown ups with social anxiousness disorder.
Showcased Short article: What member countries make up the G-20?
For much more data about analysis choices from Zacks Financial commitment Study, go to Zacks.com
This instant information alert was generated by narrative science know-how and economic details from MarketBeat in get to offer visitors with the swiftest and most accurate reporting. This tale was reviewed by MarketBeat’s editorial workforce prior to publication. Please ship any thoughts or feedback about this story to [email protected]